Yayın:
Catecholaminergic and opioidergic system mediated effects of reboxetine on diabetic neuropathic pain

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTURAN YÜCEL, NAZLI
dc.contributor.authorCAN, ÖZGÜR DEVRİM
dc.contributor.authorDEMİR ÖZKAY, ÜMİDE
dc.contributor.orcid0000-0002-0371-2703
dc.contributor.orcid0000-0002-2260-3174
dc.contributor.orcid0000-0002-6773-4266
dc.date.accessioned2025-11-13T11:25:12Z
dc.date.issued2020-01-07
dc.identifier.doihttps://doi.org/10.1007/s00213-019-05443-5
dc.identifier.endpage1145
dc.identifier.issn0033-3158
dc.identifier.issue4
dc.identifier.openalexW3000046216
dc.identifier.startpage1131
dc.identifier.urihttps://hdl.handle.net/11421/6730
dc.identifier.urihttps://doi.org/10.1007/s00213-019-05443-5
dc.identifier.volume237
dc.language.isoen
dc.relation.ispartofPsychopharmacology
dc.rightsrestrictedAccess
dc.subjectReboxetine
dc.subjectPharmacology
dc.subjectMedicine
dc.subjectNeuropathic pain
dc.subjectAllodynia
dc.subjectPregabalin
dc.subjectHyperalgesia
dc.subjectDuloxetine
dc.subjectDiabetic neuropathy
dc.subjectOpioidergic
dc.subjectDiabetes mellitus
dc.subjectOpioid
dc.subjectAnesthesia
dc.subjectInternal medicine
dc.subjectEndocrinology
dc.subjectNociception
dc.subjectReuptake inhibitor
dc.subjectSerotonin
dc.subjectReceptor
dc.subject.sdg3
dc.titleCatecholaminergic and opioidergic system mediated effects of reboxetine on diabetic neuropathic pain
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5018664863
local.authorid.openalexA5020313406
local.authorid.openalexA5017325490

Dosyalar

Koleksiyonlar

Publications